Chapter 24: Acylglycerol & Sphingolipid Metabolism

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Okay, let's unpack this.

We're diving into a dense and honestly a critical topic, the metabolism of acyloglycerols and sphingolipids.

It really is.

If you're trying to understand how a cell even holds its shape, or how your body stores massive amounts of energy, you're looking right at the heart of it.

So this deep dive is all about mapping those pathways, synthesis and degradation, step by step.

We're taking a college level look, but trying to make it make sense.

And we're focused on two major lipid families.

First up, you have the acyloglycerol.

Which for the most part means triacylglycerols, right?

Tags.

Exactly.

Those are the major lipids in your fat deposits.

They're the essential machinery for energy storage.

And you know, they're the molecules directly linked to big health issues like obesity and diabetes.

And the second family?

That would be the phospholipids and the sphingolipids.

The structural architects.

That's a perfect way to put it.

The key trick that makes them so indispensable is their amphipathic nature.

Okay, that term again.

So a water -loving head and fat -loving tails.

Precisely.

And that property allows them to spontaneously organize into the lipid bilayers that define every single cell membrane in your body.

That structure seems simple enough, but what do they do beyond just building walls?

Where does the specialization really kick in?

Oh, it elevates them entirely.

It's not just a wall.

It's a critical functional part of the cell.

Take the respiratory system, for example.

The phospholipid depomitoil lecithin is a huge component of lung surfactant.

If that one specific molecule is deficient in a premature newborn, the surface tension inside their lungs is too high.

They can't inflate.

They just can't.

And that leads directly to infant respiratory distress syndrome, or IRDS.

It's a structural defect with potentially fatal consequences.

Wow.

So a single missing lipid causes a whole system to fail.

Absolutely.

And we also see lipids as these crucial signaling hubs.

Inositol phospholipids, for instance, are the precursors for all sorts of hormone second messengers.

And what about the glycus sphingolipids?

Well, they form part of the glycolyx on the outer surface of your cells.

Think of them like identification tags.

They're crucial for cell adhesion, for recognition.

They even determine your ABO blood group.

So these lipids aren't just insulation.

They're highly specific ID tags and communication molecules.

And that's why the clinical side of this hits so hard.

When the processes that break down these complex lipids fail, we're talking about genetic defects and lysosomal enzymes, you get these devastating glycolipid storage diseases.

Things like Tay -Sachs and Goucher disease.

They show us the catastrophic consequences when this molecular waste just accumulates in the wrong places, especially the nervous system.

We'll definitely get back to those failures.

But for now, let's start with energy.

OK, let's look at how the body actually gets to the energy stored in triacylglycerols.

We're starting with catabolism, the breakdown.

Right.

And that process, called lipolysis, begins with one absolute necessity, hydrolysis.

You have to cut the fatty acids off the glycerol backbone.

Exactly.

The tags must be cleaved by a lipase to release free fatty acids in glycerol.

This happens mainly in adipose tissue.

So once those free fatty acids are released from the fat cells, how do they get around?

They aren't water soluble.

They immediately bind to the most abundant protein in your plasma, serum albumin.

And that acts as a shuttle, transporting them to the liver, heart, muscle, and other tissues where they can be oxidized for ATP or, you know, reesterified.

And one detail that's really important to remember here is that the brain does not readily use these for energy.

That's a crucial point.

It heavily prefers glucose.

OK, so what about the other piece, the glycerol backbone?

It's water soluble, but what does the body do with it?

Well, the fate of that glycerol is entirely dependent on one specific enzyme, glycerol kinase.

And not all tissues have it.

Right.

It's really only found in significant amounts in the liver, kidney, intestine, and brown adipose tissue.

If the kinase is there, it can activate the glycerol and let it reenter metabolism.

But if it's absent, like in muscle or regular white fat, then the glycerol has to travel all the way back to the liver to be processed.

That dependence on glycerol kinase actually sets up the synthesis story beautifully.

The main pathway for building both tags and phospholipids starts right there with glycerol -3 -phosphate.

It does.

And it highlights a critical link because glycerol -3 -phosphate and dihydroxyacetone

are both direct intermediates in glycolysis.

So we're bridging carbohydrate and lipid metabolism from the very first step.

Exactly.

And to kick off synthesis, both the glycerol and the fatty acids need some energy input, some activation.

Fatty acids get activated to a silica whey.

And the glycerol gets activated to G3P by that kinase if the tissue has it.

If not, say, in muscle, the G3P is formed from DHAP instead.

Once you have those activated building blocks, the common pathway can begin.

Two molecules of a silica whey combined with glycerol -3 -phosphate to form the foundational molecule for everything that follows.

And that molecule is phosphatidate.

Phosphatidate, which is 1 -ferric 2 -diacylglycerol phosphate.

OK, so phosphatidate is the central hub, the big branch point.

Let's follow the road to energy storage first making triacylglycerol.

To make a tag, that phosphatidate first has to lose its phosphate group.

It becomes 1 -ferric 2 -diacylglycerol.

And the enzyme that does this is phosphatidate phosphohydrolase, or PP.

But the really interesting thing here is that the enzyme itself is part of this family of proteins called lipids.

Yes.

And what's so special about lipids is that they're sort of regulatory double agents.

How so?

They don't just catalyze the step.

They also function as transcription factors.

They can move to the nucleus and regulate the genes that control overall lipid metabolism.

That's incredible.

So the enzyme is also part of the command structure.

It acts as an immediate gatekeeper for storage,

and it controls the cell's long -term genetic plan.

It's amazing regulatory efficiency.

So if lipids control the entry point, what controls the final rate -limiting step for storage?

That comes down to the enzyme diacylglycerol acetyltransferase, or DGAT.

DGAT catalyzes that final step, adding the third fatty acid to make triacylglycerol.

This step is significant because it's the only one specific to tag synthesis, and it's almost always the rate -limiting step.

We should probably also mention that alternative route in the gut,

the monoacylglycerol pathway.

Yes, a good point.

It's another way to get to that 1 ,4 ,2 -diacylglycerol intermediate, but primarily in the intestinal mucosa.

Okay, so we've built the storage molecule.

Now let's go back to that phosphatidate branch point and pivot to phospholipid synthesis.

Let's focus on the big ones, phosphatidylcholine, PC, and phosphatidylethanolamine, PE.

For this pathway, it's a different strategy.

Instead of activating the backbone, you activate the head group.

So you take the choline or ethanolamine,

use ATP to phosphorylate it, and then you couple it to the nucleotide CDP.

Right, you form CDP -choline or CDP -ethanolamine.

These activated nucleotide -linked head groups then react with that 1 ,4 ,2 -diacylglycerol we made earlier to form the final phospholipid.

And the liver, being resourceful, can also just convert PE to PC directly.

It can through progressive methylation.

It has a backup plan.

What about the really specialized phospholipids, like cardiolipin?

That one's crucial for mitochondria, isn't it?

It is.

Cardiolipin is almost exclusively found in the inner mitochondrial membrane, and it's vital for the electron transport chain and for apoptosis, or programmed cell death.

And the synthesis pathway is different.

A bit different, yes.

It requires activating the backbone, forming CDP -diacylglycerol first, which then reacts with another glycerol 3 -phosphate.

So let's connect this to regulation.

If a cell suddenly gets a big rush of free fatty acids, does it prioritize building storage or structure?

It follows a really logical rule.

Structure first, storage second.

The available free fatty acids that escape immediate oxidation are preferentially converted to phospholipids first.

To maintain the membranes.

Exactly.

Only after the cell has satisfied its structural and signaling needs are the leftover fatty acids channeled toward triacylglycerol synthesis for storage.

That's a very elegant system.

Okay, let's transition now to a highly specialized subset of lipids.

The glycerol ether phospholipids.

The defining feature here is the bond.

Instead of the typical ester bond, these have a chemically distinct ether linkage, a COC bond, connecting the hydrocarbon chain to the glycerol.

And the two key players are plasmelagens and the incredibly potent platelet activating factor, PAF.

Right, and their biosynthesis starts in a kind of surprising place, the peroxisomes.

And with a different precursor, DHAP, not G3P.

Correct.

The ether link is formed very early on.

Plasmelagens, for their part, make up a huge portion of the phospholipid in tissues like mitochondria and myelin.

The one that always blows my mind is PAF, platelet activating factor.

Just how potent are we talking here?

We are talking about a microscopic trigger for a massive physiological response.

Its specific structure gives it truly remarkable power.

It can aggregate platelets at concentrations as low as 10 to the minus 11 moles per liter.

That's practically nothing.

It's almost homeopathic concentrations driving a huge cellular response.

It is.

It's an incredible amount of leverage.

And its job isn't just clotting, it's also involved in inflammation, chemotaxis.

It even has hypotensive properties.

It's a signaling powerhouse that the body must control very, very carefully.

Extremely carefully.

So once these phospholipids are built, they don't just stay put.

The chapter talks about active degradation and remodeling.

Why is this constant turnover necessary?

Because the cell's needs are constantly changing.

Partial degradation, which is mediated by phospholipases, allows the cell to swap out parts of the lipid, usually the fatty acid chains, to create new signaling molecules or adapt the membrane.

That's remodeling.

And the agents doing this are the phospholipids A1, A2, B, C, and D, each one programmed to cut a specific bond.

Phospholipids A2 is especially important.

It cleaves the fatty acid at the number two position, releasing a free fatty acid and leaving behind a lysophospholipid.

And that lysophospholipid can then be immediately re -acylated with a new fatty acid, that's the remodeling, or it can be fully broken down.

Correct.

And there's also an important player in the plasma, L -TEAT.

Right, lecithin.

Cholesterol acyltransferase.

That ties into cholesterol transport.

Yes.

LCAT provides another way to make that lecithin.

It snips a fatty acid from the number two position of lecithin and transfers it directly to cholesterol, forming a cholesterol ester.

That's how most of the cholesterol esters in plasma lipoproteins get made.

So this constant remodeling is key for function, especially for getting the right fatty acids in the right place.

Saturated ones, usually in position one, but the polyunsaturated ones, the precursors for things like prostaglandins.

Are specifically incorporated into that number two position, all thanks to this continuous exchange.

OK, that covers the glycerolipids.

Let's move to the second major structural class,

the sphingolipids, and they all derive from one crucial precursor.

Ceramide.

Ceramide itself is synthesized in the ER, starting from the amino acid serine and palmitoyl coA.

But just like phosphatidate, ceramide is way more than just a building block.

Oh, absolutely.

Ceramide is a powerful, lipid -soluble second messenger.

It regulates huge cellular programs like apoptosis program cell death, as well as the cell cycle and differentiation.

So from this powerful signaling molecule, we build the complex structural sphingolipids.

Where do we go first?

To sphingondlin.

This is formed when ceramide reacts with phosphatidylcholine, the same PC from before, to make sphingomyelin and diacylglycerol.

And because it has a phosphate group, sphingomyelin is technically a phospholipid, even though its backbone is different.

Correct.

And this happens mainly in the Golgi.

And then from there, we get the huge family of glycosphhingolipids, the GSLs, which is just ceramide with sugars attached.

The simplest are the cerebrocides, like galactosylceramide, which is a major, major lipid in myelin that's formed using an activated sugar, UDP galactose.

But if you start adding more sugars, and especially acylic acid like N -acetylneuromanic acid.

Then you create the highly complex gangliosides.

And these GSLs, again, are those identification tags on the outer membrane leaflet, acting as ABO blood group substances, and even as receptors for bacterial toxins, like the one that causes cholera.

They are absolutely critical for how a cell presents itself to the outside world.

Okay, we've covered the entire landscape.

Let's finish by connecting these molecular pathways back to human disease.

Because when they fail, the results are, well, they're catastrophic.

We already mentioned IRDS as a structural deficiency.

We also see lipid loss in demyelinating diseases like multiple sclerosis.

In MS, there's a profound loss of phospholipids and sphingolipids from the white matter.

The loss is so severe that the lipid composition of the white matter actually starts to resemble that of gray matter.

But the most devastating failures have to be the sphingolipidosis, those inherited disorders of degradation.

That's right.

These are all inherited defects in the lysosomal degradation pathway.

And what's crucial to understand is that the cell is making these complex lipids just fine.

The problem is that the specific lysosomal enzyme needed to break it down is broken.

So the cellular garbage disposal is out of order.

Exactly.

And the result is a relentless toxic buildup of these lipids, especially in neurons, which leads to severe neurodegeneration.

Can you walk us through a couple of the most well -known examples just to illustrate that point?

Of course.

Let's take Tay -Sachs disease.

The deficiency is in an enzyme called hexothimididase A.

This leads to the accumulation of a specific lipid, the GM2 ganglioside.

And as that piles up in the nerve cells?

It causes mental retardation, blindness,

muscular weakness.

It's usually fatal in early childhood, all from one missing enzyme.

That's just a staggering consequence.

What about Gaucher disease?

Gaucher disease is a deficiency in fake glucosidase, which causes glucosilceramide to accumulate.

That lipid builds up in macrophages and bone marrow, leading to an enlarged liver and spleen and the painful erosion of long bones.

And the third major one is Niemann -Pick disease.

Right.

Niemann -Pick involves a deficiency in sphingomyelinase, so sphingomyelin accumulates.

And like Tay -Sachs, it's typically fatal early on.

But the good news is that while these were historically untreatable, we're now seeing real breakthroughs.

Like enzyme replacement therapy.

Yes, enzyme replacement and bone marrow transplants for some, and even promising new strategies like substrate deprivation therapy where you try to slow down the synthesis of the lipids in the first place.

That's incredible.

So, we've seen synthesis, turnover, and failure.

What's the final, concise takeaway from this deep dive?

I think you should keep three biosynthetic themes distinct in your mind.

First, tags in common phospholipids all stem from glycerol -3 -phosphate via that key intermediate

phosphatidate.

Okay, theme one.

Second, these specialized ether lipids like PAF and plasmalogens, they stem from DHAP.

And third.

All sphingolipids, sphingomyelin, the cerebrosides, the gangliosides, they all stem from that crucial signaling precursor, ceramide.

So these pathways dictate our energy balance and define every single cellular boundary we have.

All of it built and broken down via these highly regulated enzyme -driven steps.

Which leaves us with an important question for you, the learner, to consider.

We know that nerve cells are particularly vulnerable in these sphingolipidoses.

So why is the central nervous system so exquisitely sensitive to the accumulation of these specific lipids more so than other tissues that also lack the enzyme?

It just underscores the fragility and the crucial dependency of our microscopic health on precise molecular mechanics.

A fascinating point to think about.

Thank you for diving deep with us into the biochemistry of life's essential lipids.